News

Two pivotal phase 3 studies previously met their endpoints of significantly reducting daily pain compared with placebo.

The new administration options allow a single-injection option for patients that require a 320 mg dose.

Patients with IBD or arthritis were not found to be at a significantly higher risk of serious infection with a biosimilar versus originator of the common drugs.

Of patients randomized to guselkumab Q8W, 93% to 99% maintained minimally clinically important improvements in joint disease through 1 year.

A study found that high ultraprocessed food consumption increases the risk of SLE by 56%, with an even higher risk for anti-dsDNA positive SLE at 105%.

Over 70% of participants with MSK pain after COVID-19 fulfilled ACR fibromyalgia criteria in new research.

Results from INVIGORATE-2 showed IV secukinumab led to improved clinical measures of PsA, with a similar safety profile to subcutaneous secukinumab.

Secukinumab is best for severe skin involvement, while adalimumab improves synovitis in PsA. Both are effective, but larger studies are needed for long-term outcomes.

Research from Spain suggests long-term opioid use to treat fibromyalgia pain significantly raises the risk of depression, anxiety and sleep disorders in patients.

The analysis of NHANES data revealed an inverse association between dietary vitamin C intake and gout risk.

A comprehensive model of clinical and radiomic features was more accurate in distinguishing flares than either model alone.

Remission according to the simplified definition correlated with the 2016 preliminary gout remission definition and GIS score improvements.

An interim analysis of the PRO-SPIRIT study compared outcomes at 3 months after starting new treatments for psoriatic arthritis.

The rheumatology month in review emphasizes new trends in medication use and novel technologies' potential for managing fibromyalgia.

AHN Autoimmunity Institute Launches Nationwide Biobank to Advance Relapsing Polychondritis Research and Treatments

Compared with participants who gained weight or who weight remained stable, the risk of developing gout fell with increased weight loss over 1 year.

The all-optical PAT scanner reduces acquisition time from minutes to seconds and can visualize microvasculature changes to depths approaching 15 mm.

More research is needed to investigate changing trends at presentation and help to inform current treatment strategies.

The data also support the validity of further research into targeting CD-40 signaling in patients with RA not responding to treatment.

A greater portion of patients treated with bimekizumab achieved minimal clinically important differences than with placebo.

Received care was highly variable among ethnicities and gender and often contradicted current guidelines.

In other populations, JAKis demonstrated at least a similar pain benefit to b/tsDMARDs from baseline.

This clinical quiz, our last in a series of 4, focuses on recommendations for special populations and long-term management from the 2020 ACR gout guidelines.

Higher Life’s Essential 8 score was associated with higher CVH scores in US adults.

Younger people and people without European origin were less likely to adhere to urate-lowering therapy.

There were no differences in the treatment effect of ertugliflozin on gout-related outcomes in subgroups based on eric acid quintile or other baseline characteristics.

Further data will be presented at the 2024 AANEM Meeting in Georgia in October.

The therapy demonstrated superior efficacy in combination with SOC over SOC alone.

Concomitantly, other treatment modalities such as physical and occupational therapy, anticonvulsants, topical analgesics, and psychosocial treatment have increased.